Abstracts tagged "Cohort Study"

Abstract Number: 0711 • ACR Convergence 2023
IgA Vasculitis in a Diverse Adult Patient Population
Michelle Toker¹, Urmi Khanna¹, Roya Nazarian¹, Adhya Mehta², Bibi Ayesha¹, Anand Kumthekar¹ and Benedict Wu¹, ¹Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, ²Jacobi Medical Center, Bronx, NY
Background/Purpose: Immunoglobulin-A (IgA) Vasculitis (IgAV) is a small-vessel vasculitis that is primarily diagnosed based on the European League Against Rheumatism (EULAR) criteria. There is limited…
Abstract Number: 1199 • ACR Convergence 2023
Association of Dipeptidyl Peptidase-4 Inhibitor Use for Type 2 Diabetes and Incidence of OA in Taiwan
Hsiang-Yen Lee¹, Ching-Kuei Chang¹, Tzu-Min Lin¹, Tzu-Tung Ku², Jin-Hua Chen², Yu-Hsiu Chen³, Shu-Chuan Chen⁴ and Chi-Ching Chang², ¹Taipei Medical University Hospital, Taipei, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Tri-Service General Hospital, Taipei, Taiwan, ⁴Idaho State University, Idaho State Pocatello, ID
Background/Purpose: Cellular senescence is involved in osteoarthritis (OA) development. Dipeptidyl Peptidase-4 (DPP4) is associated with senescence in OA chondrocytes. It is uncertain whether DPP4 inhibitor…
Abstract Number: 2044 • ACR Convergence 2023
Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population
Alhanouf Alsaleem, Sulaiman Al-Mayouf and Shahad Alansari, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
Background/Purpose: IFN-mediated diseases are mendelian innate immunodysregulatory disorders that present early in life with fevers, sterile organ inflammation, and a high type-I IFN-response gene signature…
Abstract Number: 2533 • ACR Convergence 2023
Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study
Naohiro Sugitani¹, Eiichi Tanaka², Eisuke Inoue³, Mai Abe¹, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai⁴, Rei Yamaguchi¹, Katsunori Ikari⁵, Ayako Nakajima⁶, Hisashi Yamanaka⁷ and Masayoshi Harigai⁸, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjunku-ku, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Research Administration Center, Showa University, Shinagawa-ku, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine,, Shinjunku-ku, Japan, ⁵Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁶Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ⁷Sanno Medical Center, Tokyo, Japan, ⁸Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have been reported to have higher mortality rates than the general population. Our previous report showed that the standardized…
Abstract Number: 0432 • ACR Convergence 2023
Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice
Rodolfo Perez-Alamino¹, Carolina Isnardi², Enrique Soriano³, Luciano Lo Giudice⁴, johana zacariaz hereter⁴, Gustavo Casado⁵, Victor Caputo⁵, Andrea Schmichowski⁵, Cecilia Romeo⁵, Estela Rivero⁵, Florencia Savy⁶, Mercedes García⁷, Olga Romano¹, Hernan Maldonado Ficco⁸ and Gustavo Citera², ¹Hospital Avellaneda, Tucuman, Argentina, ²IREP, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Militar Central, Buenos Aires, Argentina, ⁶HIGA San Martin, La Plata, Argentina, ⁷Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁸Hospital San Antonio de Padua, Río Cuarto, Argentina
Background/Purpose: Different guidelines recommend the use of tofacitinib either in monotherapy or combined with methotrexate (combination therapy) in patients with rheumatoid arthritis (RA) with an…
Abstract Number: 0762 • ACR Convergence 2023
Liver Disease Is a Common Feature of HA20 That Causes Significant Morbidity Associated with Interferon Induction
Magdalena Harasimowicz¹, Deborah Stone², Manuel Carpio Tumba¹, Tina Romeo², Urekha Karri¹, Patrycja Hoffmann³, Helen Leavis⁴, Alexander Miethke⁵, Theo Heller², Anjali Rai², Ivona Aksentijevich², amanda ombrello⁶, Daniel Kastner⁷ and Daniella Schwartz¹, ¹University of Pittsburgh, Pittsburgh, PA, ²NIH, Bethesda, MD, ³NIH, Vienna, VA, ⁴Infection Immunity Utrecht, Utrecht, Netherlands, ⁵Cincinnati Children's Hospital, Cincinnati, OH, ⁶National Institutes of Health, Rockville, MD, ⁷National Human Genome Research Institute, Bethesda, MD
Background/Purpose: Heterozygous loss-of-function TNFAIP3 mutations cause A20 haploinsufficiency (HA20), an early-onset immune dysregulatory disease1. While HA20 was initially described as an inherited form of Behcet’s…
Abstract Number: 1243 • ACR Convergence 2023
Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study
Ryan Mitacek, Qiong Liu, Linda Wagner-Weiner, Shireen Hashmat and Anthony Chang, University of Chicago, Chicago, IL
Background/Purpose: Lupus nephritis (LN) is associated with significant morbidity and mortality. The 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria and the NIH…
Abstract Number: 2142 • ACR Convergence 2023
Adherence Patterns in Rheumatoid Arthritis Patients Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis Factor α Inhibitor (TNFi) After the Addition of a Black Box Warning to JAK Inhibitors
W. Cliff Rutter, Kunal Patel, Samantha Delgado, Guy Cozzi, Elisea Avalos-Reyes, Will Cavers, Chen Liu, Rashmi Grover, Lucia Feczko and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: In 2021, the FDA concluded that there is an increased risk of serious heart-related events with the Janus Kinase (JAK) inhibitor tofacitinib, which is…
Abstract Number: 2570 • ACR Convergence 2023
Thrombosis in Patients with VEXAS Syndrome: A Retrospective Cohort Study
Atefeh Ghorbanzadeh¹, Yael Kusne², Alina Dulau-Florea³, Ruba Shalhoub³, Pedro Alcedo³, Khanh Nghiem³, Marcela Ferrada⁴, alexander hines¹, Sumith Panicker³, amanda ombrello⁵, Kaaren K. Reichard¹, Ivana Darden³, Wendy Goodspeed³, Lorena wilson³, Horatiu Olteanu¹, Terra L. Lasho¹, Daniel Kastner⁶, Kenneth Warrington¹, Abhishek A. Mangaonkar¹, Ronald Go¹, David Beck⁷, Mrinal S. Patnaik¹, Neal S. Young⁸, Katherine R. Calvo³, Ana Casanegra⁹, Peter Grayson¹⁰, Matthew Koster¹, Colin O Wu³, Damon E. Houghton⁹, Bhavisha Patel¹¹, Yogen Kanthi¹² and Emma M. Groarke¹³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Phoenix, AZ, ³National Institutes of Health (NIH), Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁵National Institutes of Health, Rockville, MD, ⁶National Human Genome Research Institute, Bethesda, MD, ⁷New York University, New York, NY, ⁸National Institutes of Health (NIH), Rochester, MD, ⁹Mayo Clinic, Rochester, MD, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹¹National Institutes of Health, Beltsville, MD, ¹²National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, ¹³Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, due to somatic mutations in the UBA1 gene, is an autoinflammatory disorder associated with an increased…
Abstract Number: 0437 • ACR Convergence 2023
Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis
Xavier Sendaydiego¹, Laura Gold², K Wysham³, Jean liew⁴, Maureen Dubreuil⁵, James Andrews¹, Pankti Reid⁶, David Liew⁷, Radjiv Goulabchand⁸, Abha Singh⁹, Grant Hughes¹, Mathilde Pioro¹, Jeffrey Sparks¹⁰, Jeffrey Jarvik², Siddharth Singh⁹ and Namrata Singh¹¹, ¹University of Washington, Seattle, WA, ²Department of Radiology and University of Washington Clinical Learning, Evidence, and Research (CLEAR) Center for Musculoskeletal Disorders, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Boston University, Boston, MA, ⁵Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁶University of Chicago Medical Center, Chicago, IL, ⁷Austin Health, Heidelberg, Australia, ⁸St. Eloi Hospital, Department of Internal Medicine and Multi-Organic Diseases, Montpellier, France, ⁹University of California San Diego, San Diego, CA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹University of Washington, Bellevue, WA
Background/Purpose: Concern has arisen over the safety of Janus kinase inhibitors (JAKi) regarding cardiovascular (CV) outcomes in patients with rheumatoid arthritis (RA) with CV risk…
Abstract Number: 0786 • ACR Convergence 2023
A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort
Anna Arar, Diane L. Kamen, Paul Nietert and Melissa Cunningham, Medical University of South Carolina, Charleston, SC
Background/Purpose: Manifestations of systemic lupus erythematous (SLE) vary in severity and presentation; lupus nephritis (LN) affects up to half of SLE patients and confers a…
Abstract Number: 1254 • ACR Convergence 2023
Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE)
Amita Aggarwal¹, Ranjan Gupta², Liza Rajasekhar³, Ashish J Mathew⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Vineeta Shobha⁷, Bidyut Das⁸, Manish Rathi⁹, Avinash Jain¹⁰ and Able Lawrence¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ²All India Institute of Medical Sciences, New Delhi, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴Christian Medical College, Vellore, India, ⁵Govt of West Bengal, Kolkata, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ⁷St. John's National Academy of Health Science, Bangalore, India, ⁸SCB medical college, Cuttack, India, ⁹Postgraduate Institute of Medical education and Research, Chandigarh, India, ¹⁰SMS Medical College, Lucknow, India
Background/Purpose: Juvenile onset SLE (jSLE) has more severe disease and has poorer outcome as compared to adults SLE. Ethnicity affects clinical course and disease outcome…
Abstract Number: 2215 • ACR Convergence 2023
Can Axial Spondyloarthritis Unequivocally Be Diagnosed by Rheumatologists in Patients with Chronic Back Pain of Less Than Two Years Duration? The Primary Outcome of the Two-year SPondyloArthritis Caught Early (SPACE) Cohort
Mary Lucy marques¹, Sofia Ramiro², Miranda Van Lunteren³, Rosalinde Stal³, Robert BM Landewé⁴, Marleen van de Sande⁵, Karen Minde Fagerli⁶, Inger Jorid Berg⁶, Maikel van oosterhout⁷, Sofia Exarchou⁸, Roberta Ramonda⁹, Désirée van der Heijde² and Floris Van Gaalen³, ¹Leiden University Medical Center; Centro Hospitalar e Universitário de Coimbra (Department of Rheumatology), Coimbra, Portugal, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ⁵Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ⁶Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁷Groene Hart Ziekenhuis, Gouda, Netherlands, ⁸Lund University, Åkarp, Sweden, ⁹University of Padova, Department of Rheumatology, Padova, Italy
Background/Purpose: Unacceptable diagnostic delay in axial Spondyloarthritis (axSpA) remains an issue. In 2008, the longitudinal SPondyloArthritis Caught Early (SPACE)-cohort started to assess the prevalence of…
Abstract Number: 2573 • ACR Convergence 2023
Prevalence of Pulmonary Hypertension in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features and Its Effect on Lung Disease Progression and Mortality
Michelle Ghebranious, Elena Joerns, Traci Adams and Trushil Shah, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) that manifests with interstitial pneumonia and features of autoimmunity while…
Abstract Number: 0471 • ACR Convergence 2023
Knowledge and Misconceptions About Contraception Among Individuals with Inflammatory Arthritis and Lupus-like Diseases
Caroline Siegel¹, Medha Barbhaiya², Lucy Masto¹, Amaya Smole¹, Bessie Stamm¹, Jonah Levine¹, Sarah Lieber², Lisa Mandl², Michael Lockshin² and Lisa Sammaritano², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Rheumatologists do not consistently provide contraceptive counseling for patients with systemic rheumatic disease (SRD). As contraception considerations may differ based on SRD, we compared…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].